60
Articles Count
174772
Viewing Count
Minhua Chu

Dean of Research Institute

April licensing trends show Chinese biotechs expan...
Minhua Chu · 1 months ago
From March 2021 to April 2022, there have been seven deals in ophthalmology. Ophthalmic drugs have become an important target of in-licensing deals in China.
Further information
China Deals Tracker
Adagene-Sanofi’s $2.5B deal tops March deals in C...
Minhua Chu · 2 months ago
Several early-stage out-licensing deals inked by Chinese biotech firms to carry their in-house technology platforms and pipelines to the global market marked the dealmaking space of March 2022.
Further information
China Deals Tracker
China’s new regulations on human genetic resource...
Minhua Chu · 2 months ago
Though China still requires that foreign companies seek approval before using human genetic resources (HGR) in their clinical trials, a new regulation is relaxing the definition of ‘foreign entities’ and clarifying when approval is needed. This is intended to make it easier for biotech firms to start clinical trials.
Further information
Regulatory
China’s CDE offers assistance and encourages comm...
Minhua Chu · 3 months ago
China’s CDE has told drugmakers to communicate more with them and will offer guidance for breakthrough therapy applications.
Further information
Regulatory
Huadong Medicine lands three in-licensing deals in...
Minhua Chu · 3 months ago
Huadong Medicine announced a series of three in-licensing deals with a combined value of $1.667 billion, pushing the total deal value for February to $1.883 billion, edging over the $1.681 billion the previous month.
Further information
China Deals Tracker
China’s CDE issues new guidelines for COVID-19 dr...
Minhua Chu · 4 months ago
The CDE issued a new batch of guidelines that covers the subjects, primary endpoints and design of clinical trials for COVID-19 drugs. The move came six days after the NMPA granted conditional approval for Pfizer's Paxlovid.
Further information
Regulatory
Chinese drug developer looks to enter the U.S. mar...
Minhua Chu · 4 months ago
In the first month of 2022, 16 licensing deals related to innovative drugs were announced, including eight in-licensing, four out-licensing and four domestic deals.
Further information
China Deals Tracker
New drug approvals in 2021: 64 new molecular entit...
Minhua Chu · 5 months ago
Chinese drug regulators are approving more new drugs and more of them are developed by local players.
Further information
China NMPA Approval Tracker
China defines cell therapy as drug with new GMP
Minhua Chu · 5 months ago
The release of good manufacturing practices for cell therapy this year is an important step in regulating cell therapies.
Further information
Regulatory
2021 wraps up with multi-billion dollar deals
Minhua Chu · 5 months ago
In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms.
Further information
China Deals Tracker
READ MORE

Personal Information

Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement